Breast-conserving surgery (BCS) is the standard of care for early
breast cancer patients, while the high ratio of reoperation is still a challenge due to inaccurate margin assessments. In patients with locally advanced or advanced
breast cancer,
radiotherapy is an important treatment for local control or improvement of quality of life. However, enhancing sensitization to
radiotherapy is an unmet medical need. To solve the above clinical predicaments, a
glutathione (GSH) exhausting virus-like
silicon dioxide nanoprobe with Gd coating and
folic acid (FA) modification is designed. After loading ICG in the mesopores, the VGd@ICG-FA probe efficiently targets
tumor cells with high resolution, due to its virus-like morphology and
folate acid anchoring. Especially, the fabricated nanoprobe enables the identification of tiny
cancers and navigates precise surgery under NIR-II fluorescence imaging. Moreover, after the nanoprobes enter into the cytoplasm of
cancer cells, tetrasulfide linkages in the
silica framework are broken under the triggering of high GSH concentrations. In turn, the broken framework exhausts GSH to disrupt intracellular
reactive oxygen species (ROS) homeostasis, and Gd produces more ROS under
radiotherapy, further activating ferroptosis, and resulting in the enhancement of
radiotherapy in
breast cancer. Therefore, our nanoprobe exhibits tremendous potential as a NIR-II fluorescence imaging agent with no systematic side effects for precise
cancer surgery and nanotherapeutics for boosting radiation sensitivity in future clinical translation of
breast cancer.